Arena Investors’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Arena Investors’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$11.7K	Hold	333,333	–	–	0.09%	15
2024 Q1	$17.3K	Hold	333,333	–	–	0.26%	8
2023 Q4	$21.5K	Hold	333,333	–	–	0.11%	12
2023 Q3	$73.3K	Hold	333,333	–	–	0.08%	29
2023 Q2	$35K	Hold	333,333	–	–	0.03%	51
2023 Q1	$16.4K	Hold	333,333	–	–	0.01%	58
2022 Q4	$86.7K	Hold	333,333	–	–	0.08%	53
2022 Q3	$18.9K	Hold	333,333	–	–	0.01%	122
2022 Q2	$30K	Buy	+333,333	New	+$73.9K	0.01%	120

Other funds holding CLDI.WS

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Arena Investors's CLDI.WS Position: Q2 2024 in Review

Arena Investors held its Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) position steady in Q2 2024 at 333,333 shares worth $11.7K. The position accounts for 0.09% of the portfolio, ranked #15.

Arena Investors first reported a position in CLDI.WS in Q2 2022 and has held it in 9 quarters since. The position peaked at $86.7K in Q4 2022. 15 funds tracked by Wall St. Rank hold CLDI.WS as of Q2 2024.

Arena Investors held 333,333 shares of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 worth $11.7K as of Q2 2024.
Arena Investors left its Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 share count unchanged in Q2 2024.
Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 made up 0.09% of Arena Investors's portfolio in Q2 2024, its #15 holding.
Arena Investors first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q2 2022 and has held it in 9 quarters since.
Arena Investors's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $86.7K in Q4 2022.
15 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q2 2024.

Based on Arena Investors's 13F filing for Q2 2024, filed 14 Aug 2024.